Inactive Instrument

Myovant Sciences Ltd.

MYOV

BMG637AM1024

Biotechnology & Medical Research

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

October 21, 2022 at 04:06 pm EDT

Myovant Sciences Ltd. at its 2022 Annual General Meeting of Shareholders held on October 21, 2022, approved the appointment of Shigeyuki Nishinaka as a director for a one-year term.

Latest news about Myovant Sciences Ltd.

Sumitomo Pharma Unit Closes $1.7 Billion Purchase of Myovant Sciences	23-03-14	MT
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P Biotechnology Select Industry Index	23-03-10	CI
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P TMI Index	23-03-10	CI
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P Global BMI Index	23-03-10	CI
Sumitovant Biopharma Ltd. completed the acquisition of remaining 47.83% stake in Myovant Sciences Ltd..	23-03-09	CI
Myovant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-26	CI
Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q3 Revenue $100.2M	23-01-26	MT
Insider Sell: Myovant Sciences	23-01-20	MT
Lyell Immunopharma Names Lynn Seely as Chief Executive	22-12-15	MT
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources	22-11-16	CI
Evercore ISI Downgrades Myovant Sciences to In Line From Outperform With $27 Price Target	22-10-26	MT
Myovant Sciences Fiscal Q2 Loss Widens, Revenue Rises	22-10-26	MT
Myovant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-10-26	CI
Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q2 Revenue $104.8M	22-10-26	MT
SVB Securities Downgrades Myovant Sciences to Market Perform From Outperform, Adjusts Price Target to $27 From $23	22-10-25	MT
Buying Spree Pulls Up Japanese Stocks; Sumitomo Pharma Unit to Buy Remaining 48% of Myovant Sciences for $1.7 Billion	22-10-25	MT
Sumitomo Pharma Unit to Acquire Remaining 48% of Myovant Sciences for $1.7 Billion	22-10-25	MT
Myovant Sciences Share Rise After Agreement to be Fully Acquired by Sumitovant Biopharma	22-10-24	MT
Baird Downgrades Myovant Sciences to Neutral From Outperform, Raises Price Target to $27 From $20	22-10-24	MT
Japan's Sumitomo Pharma to buy rest of Myovant in sweetened deal	22-10-24	RE
Myovant Sciences to be Fully Acquired by Sumitovant Biopharma	22-10-24	MT
Japan's Sumitomo Pharma to buy rest of Myovant for $27 per share	22-10-24	RE
Sumitovant Biopharma to buy Myovant for $27 per share	22-10-23	RE
Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion.	22-10-22	CI
Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director	22-10-21	CI

Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company's two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research